This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): RTX, resiniferatoxin
Description: RTX is a small molecule that can be delivered to the bladder to desensitize specific nerves called afferent neurons.
Deal Structure: Icos has entered into a licensing agreement with Afferon Corporation related to RTX. Under the terms of this agreement, Icos has exclusive worldwide license rights for commercial use of RTX for the treatment of bladder disease or function. Icos is responsible for the costs of developing and commercializing RTX and related analogues. Afferon receives certain periodic payments and is entitled to future success-based milestone payments and royalties upon sales of marketed products, if any, resulting from this arrangement.
In January 2007, Lilly completed its acquisition of ICOS. As a result of closing the transaction, Lilly has acquired all of the outstanding shares of ICOS common stock at a price of $34 per share, for a total of approximately $2.3 billion.
Partners: Afferon Corporation
Additional information available to subscribers only: